Erin Hugger's Email Addresses & Phone Numbers

Currently, Vice President of Business Development & Strategy at Incyte Corporation, an Oncology biotech company based in Wilmington, Delaware. Fourteen years of prior Big Pharma experience, including 8 years within drug discovery & development at GlaxoSmithKline (7 years) & Pharmacia (1 year) and 6+ years in World-Wide Business Development (WWBD) in R&D at GSK. Six+ years of...

Currently, Vice President of Business Development & Strategy at Incyte Corporation, an Oncology biotech company based in Wilmington, Delaware. Fourteen years of prior Big Pharma experience, including 8 years within drug discovery & development at GlaxoSmithKline (7 years) & Pharmacia (1 year) and 6+ years in World-Wide Business Development (WWBD) in R&D at GSK. Six+ years of experience within World-Wide Business Development (WWBD) at GSK: --1Q2014 - 2Q2015: Senior Director Scientific Licensing & Interim Head Oncology BD within WWBD at GSK --1Q2012 - 4Q2013: Director Scientific Licensing Infectious Diseases & Diseases of Developing World, WWBD at GSK. Responsible for scouting / leading evaluation of opportunities for partnering with GSK Infectious Diseases. Also provided support to GSK's Diseases of the Developing World (DDW) group focused on treatments for malaria, TB, kinetoplastids. --1Q2010-1Q2012: Director of Scientific Licensing Rare Diseases, WWBD at GSK, where I supported the identification, evaluation and due diligence activities for opportunities of interest for licensing by GSK Rare Diseases. --3Q2008-1Q2010: Provided technical support and leadership on the evaluation of opportunities for Infectious Diseases, Neurosciences and CV/Metabolic Therapeutic Areas (TA). Also worked with my VP & colleagues in M&A on the technical evaluation of company R&D pipelines. Led technical teams on the evaluation of the following deals subsequently signed by GSK and: Amicus Therapeutics: GSK granted exclusive world-wide license to Amigal for Fabry Disease (Rare Diseases); Hospital San Raffaele - Telethon Institute of Gene Therapy (Hematopoietic stem cell gene therapy alliance for ADA-SCID and other monogenic diseases - WAS, MLD, others; Rare Diseases); Angiochem: Research collaboration in LSDs employing Angiochem's BBB Trojan Horse Platform (Rare Diseases) Regulus: collaborate on anti-miR-122 microRNAs for HCV (Infectious Diseases)Vice President Business Development @ Currently, Vice President of Business Development & Strategy at Incyte Corporation, an Oncology / Immuno-Oncology biotech company based in Wilmington, Delaware. From June 2015 to Present (7 months) Senior Director Scientific Licensing & Interim Head Oncology BD, World-Wide Business Development @ Executed business development strategy for Oncology R&D at GSK, including scouting, evaluation, and negotiation of new deals with potential partners, as well as overseeing existing R&D alliances with GSK Alliance Management team. Broad TA expertise including Infectious Diseases, Neglected Tropical Diseases, Rare Diseases, Neurosciences, Oncology (tumor signaling, immuno-oncology, epigenetics), and Diagnostics. Range of TA expertise includes evaluation of technology platforms & early stage preclinical programs up to pre-registration assets; this includes review of Biopharms (mAbs, proteins, peptides, cell therapies, gene therapies) and small molecules. Previous experience triaging / reviewing marketed assets on stratgy for TAs/ business units. From January 2014 to May 2015 (1 year 5 months) Director of Scientific Licensing for Infectious Diseases, WWBD @ Alongside the BD leadership team, leads the scouting and evaluation of opportunities for potential partnership with GSK Infectious Diseases. Responsible for leading all due diligences for GSK Infectious Diseases. From January 2012 to December 2013 (2 years) Director of Scientific Licensing for Rare Diseases, WWBD @ Director of Scientific Licensing for Rare Diseases within World-Wide Business Development at GlaxoSmithKline Led the identfication and evalution of opportunities for potential partnership with GSK Rare Diseases From February 2010 to January 2012 (2 years) Manager Scientific Licensing, World-Wide Business Development @ Generalist working across all therapy areas as licensing support in GSK WWBD. Worked with Licensing Directors & VP on evaluation of opportunities. Led diligence teams on review of preclinical & clinical stage opportunities in Infectious Diseases, CV / Metabolic, Neurosciences. From September 2008 to February 2010 (1 year 6 months) Investigator / Manager of Drug Metabolism & Pharmacokinetics @ Program team representative for DMPK lead optimization programs in oncology & oncology supportive care. Also, supervised staff and departmental MDR1-MDCK and Bcrp-MDCK cell transporter assays for all site programs (Infectious Diseases, Bone Diseases, Oncology, Supportive care). Provided PK & TK support to program teams. Extensive use with WinNonlin for PK modelling. With this and prior job in PharmDev, contributed to 7 candidate selections in 7 years. Contributed to DMPK IND summary reports & Clinical Investigator Brochures. From July 2003 to September 2008 (5 years 3 months) Principle Scientist, Pharmaceutical Development @ Served as program matrix team leader for PharmDev on a variety of programs in drug discovery / development at GSK. Responsible for physicochemical characterization studies on candidates in lead optimization phase, including assessment of solubility, solution and solid-state stability, crystallinity. Provided formulation support to DMPK & Safety Assessment as needed on advanced lead compounds. From October 2001 to July 2003 (1 year 10 months) Graduate Research Assistant @ Experience with Caco-2, wt-MDCK and MDR1-MDCK cell culture, radioisotopes, HPLC. From January 1998 to October 2001 (3 years 10 months) Graduate Student Intern @ Student intern in the Drug Absorption & Transport group within Pharmaceutical Development. Gained experience in TECAN programming for automation of cellular transport studies using Caco-2 and MDCK cells. From July 2000 to April 2001 (10 months) Ph.D., Pharmaceutical Chemistry @ The University of Kansas From 1997 to 2001 B.S., Chemistry (biochemistry emphasis) @ University of Tulsa From 1993 to 1997 Claremore High School From 1991 to 1993 Erin Hugger is skilled in: Drug Discovery, Oncology, Clinical Development, Infectious Diseases, Pharmacokinetics, Pharmaceutical Industry, Cell, Business Development, Strategy, Drug Development, Neglected Tropical Diseases, Hematology, Rare Diseases, Licensing, Licensing Negotiations